Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

About Concert Pharmaceuticals

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company's deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNCE
  • CUSIP:
Key Metrics:
  • Previous Close: $9.67
  • 50 Day Moving Average: $9.60
  • 200 Day Moving Average: $9.63
  • 52-Week Range: $7.11 - $15.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.67
  • P/E Growth: 0.00
  • Market Cap: $207.82M
  • Outstanding Shares: 22,274,000
  • Beta: 1.73
Profitability:
  • Net Margins: -363.29%
  • Return on Equity: -33.68%
  • Return on Assets: -29.50%
Debt:
  • Current Ratio: 15.93%
  • Quick Ratio: 15.93%
Additional Links:
Companies Related to Concert Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.50 (173.31% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017AegisInitiated CoverageBuy$25.00View Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00View Rating Details
9/27/2016Stifel NicolausReiterated RatingBuy$23.00View Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details
6/24/2015Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$24.00 -> $27.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017        
11/8/2016Q316($0.63)($0.51)ViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)ViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.24 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)$1.80$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.38 millionViewN/AView Earnings Details
11/12/2014Q314($0.49)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.42)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
Current Year EPS Consensus Estimate: $-2.36 EPS
Next Year EPS Consensus Estimate: $-2.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20161($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Concert Pharmaceuticals (NASDAQ:CNCE)
Insider Ownership Percentage: 15.30%
Institutional Ownership Percentage: 60.37%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
DateHeadline
News IconAnalysts Take the Wheel on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:CNCE)
aikenadvocate.com - February 22 at 4:32 PM
News IconWhat the Technicals Are Saying About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Midway Monitor (NASDAQ:CNCE)
midwaymonitor.com - February 22 at 4:32 PM
News IconMomentum Watch on Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - BVN (NASDAQ:CNCE)
bvnewsjournal.com - February 18 at 10:41 AM
News IconConcert Pharmaceuticals Inc CNCE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CNCE)
www.bioportfolio.com - February 10 at 4:39 PM
News IconEye on Technicals Concert Pharmaceuticals Inc. (CNCE) - Providence Standard (NASDAQ:CNCE)
providencestandard.com - February 8 at 4:42 PM
News IconInvestor Notebook: Focusing in on Shares of Concert Pharmaceuticals Inc. (CNCE) - Sherwood Daily (NASDAQ:CNCE)
sherwooddaily.com - February 3 at 4:40 PM
News IconTrading Scope: Checking on Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - The Tribune (NASDAQ:CNCE)
lakecitytribune.com - January 30 at 10:20 PM
News IconTrading Views: RSI, MA, and ADX Review for Concert Pharmaceuticals Inc. (CNCE) - Sherwood Daily (NASDAQ:CNCE)
sherwooddaily.com - January 30 at 10:20 PM
News IconVolatility Numbers in View for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Gilbert Daily (NASDAQ:CNCE)
gilbertdaily.com - January 30 at 7:23 AM
News IconADX Watch on Shares of Concert Pharmaceuticals Inc. (CNCE) - Sherwood Daily (NASDAQ:CNCE)
sherwooddaily.com - January 27 at 5:45 PM
seekingalpha.com logoConcert Pharmaceuticals Set For A Transformational 2017 - Concert ... - Seeking Alpha (NASDAQ:CNCE)
seekingalpha.com - January 26 at 10:33 PM
News IconTechnical Indicator Review on Shares of Concert Pharmaceuticals Inc. (CNCE) - Sherwood Daily (NASDAQ:CNCE)
sherwooddaily.com - January 24 at 4:57 PM
zacks.com logoConcert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S. (NASDAQ:CNCE)
www.zacks.com - January 23 at 4:40 PM
insidermonkey.com logoHere’s What A Concert Pharmaceuticals Inc (CNCE) Data Win Might Mean For The Company (NASDAQ:CNCE)
www.insidermonkey.com - January 23 at 4:40 PM
News IconTechnicals in Focus for Concert Pharmaceuticals Inc. (CNCE) - Sherwood Daily (NASDAQ:CNCE)
sherwooddaily.com - January 22 at 9:24 PM
News IconInvesting Focus: Indicators in View on Shares of Concert Pharmaceuticals Inc. (CNCE) - Rives Journal (NASDAQ:CNCE)
rivesjournal.com - January 21 at 4:25 PM
investors.com logoConcert Pharmaceuticals shares lifted as Cystic Fibrosis drugs gets orphan status (NASDAQ:CNCE)
www.proactiveinvestors.com - January 20 at 5:34 PM
streetinsider.com logoConcert Pharma (CNCE) CTP-656 Granted FDA Orphan Drug Designation in CF (NASDAQ:CNCE)
www.streetinsider.com - January 20 at 5:34 PM
News IconWhy Concert Pharmaceuticals Inc (NASDAQ:CNCE) Stocks Are Trading Up? (NASDAQ:CNCE)
stockmarketdaily.co - January 20 at 5:34 PM
us.rd.yahoo.com logoConcert Pharmaceuticals Receives FDA Orphan Drug Designation for CTP-656 for the Treatment of Cystic Fibrosis (NASDAQ:CNCE)
us.rd.yahoo.com - January 20 at 5:34 PM
News IconSell-side Consensus Sees Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Going Where Near-Term? - Aiken Advocate (NASDAQ:CNCE)
aikenadvocate.com - January 18 at 4:43 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Beacon (NASDAQ:CNCE)
wsbeacon.com - January 18 at 4:43 PM
4-traders.com logoTuesday Sector Laggards: Drugs, Biotechnology Stocks (NASDAQ:CNCE)
www.4-traders.com - January 17 at 5:11 PM
streetinsider.com logoConcert Pharma (CNCE) Initiates Placebo-Controlled Phase 2 of CTP-656 in CF in U.S.; Plans Open-Label Phase 2 in EU in Q2 (NASDAQ:CNCE)
www.streetinsider.com - January 17 at 5:11 PM
finance.yahoo.com logo7:04 am Concert Pharmaceuticals provides further details on CTP-656 development in U.S. and Europe; FDA requiring adequate washout period (NASDAQ:CNCE)
finance.yahoo.com - January 17 at 5:11 PM
streetinsider.com logoConcert Pharma (CNCE) Initiates Placebo-Controlled Phase 2 of CTP-656 in CF in U.S.; Plans Open-Label Phase 2 in ... - StreetInsider.com (NASDAQ:CNCE)
www.streetinsider.com - January 17 at 8:54 AM
finance.yahoo.com logoConcert Pharmaceuticals Provides Further Details on CTP-656 Development in U.S. and Europe (NASDAQ:CNCE)
finance.yahoo.com - January 17 at 8:54 AM
News IconUpside Alert: Delving into Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Prospect Journal (NASDAQ:CNCE)
prospectjournal.com - January 16 at 9:27 PM
investornewswire.com logoSentiments And Ratings Alert: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Investor Newswire (NASDAQ:CNCE)
www.investornewswire.com - January 15 at 9:19 PM
News IconWill The Needle Move For Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CNCE)
wsbeacon.com - January 14 at 4:27 PM
investornewswire.com logoConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:CNCE)
www.investornewswire.com - December 30 at 9:49 PM
nasdaq.com logoWill Concert Pharmaceuticals (CNCE) Continue to Surge Higher? - Nasdaq (NASDAQ:CNCE)
www.nasdaq.com - December 30 at 2:48 AM
finance.yahoo.com logoWill Concert Pharmaceuticals (CNCE) Continue to Surge Higher? (NASDAQ:CNCE)
finance.yahoo.com - December 29 at 4:45 PM
businesswire.com logoConcert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis - Business Wire (press release) (NASDAQ:CNCE)
www.businesswire.com - December 21 at 10:11 PM
News IconTicker Watch: Technical Views on Shares of Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 21 at 10:11 PM
publicnow.com logoConcert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-656 for the Treatment of Cystic Fibrosis (NASDAQ:CNCE)
www.publicnow.com - December 21 at 5:07 PM
News IconCan This Stock Gain Traction: Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Prospect Journal (NASDAQ:CNCE)
prospectjournal.com - December 20 at 8:41 AM
capitalcube.com logoETFs with exposure to Concert Pharmaceuticals, Inc. : December 19, 2016 (NASDAQ:CNCE)
www.capitalcube.com - December 20 at 8:41 AM
insidermonkey.com logoHow Concert Pharmaceuticals Inc (CNCE) Stacks Up Against Its Peers (NASDAQ:CNCE)
www.insidermonkey.com - December 18 at 4:25 PM
istreetwire.com logoMomentum Stocks in Focus: Concert Pharmaceuticals, Inc. (CNCE), Quad/Graphics, Inc. (QUAD), Southside ... - iStreetWire (NASDAQ:CNCE)
istreetwire.com - December 17 at 4:37 PM
News IconMeasuring the Levels on Shares of Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 17 at 2:52 AM
News IconTrading Views: RSI, MA, and ADX Review for Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 15 at 4:47 PM
streetinsider.com logoConcert Pharma (CNCE) CTP-543 Emerges from Phase 1 - StreetInsider.com (NASDAQ:CNCE)
www.streetinsider.com - December 15 at 4:47 PM
us.rd.yahoo.com logo7:30 am Concert Pharmaceuticals announces 'positive' top-line Phase 1 results; CTP-543 to advance into Phase 2 in 1Q17 (NASDAQ:CNCE)
us.rd.yahoo.com - December 14 at 5:26 PM
finance.yahoo.com logoConcert Pharmaceuticals Announces CTP-543 Positive Top-Line Phase 1 Results (NASDAQ:CNCE)
finance.yahoo.com - December 14 at 5:26 PM
News IconTechnical Action Update on Shares of Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 13 at 7:36 AM
News IconTraders are Keeping Track of Technicals on Shares of Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 9 at 9:42 PM
News IconChart Inspection on Shares of Concert Pharmaceuticals Inc. (CNCE) - Yankee Analysts (NASDAQ:CNCE)
yankeeanalysts.com - December 8 at 4:02 PM
capitalcube.com logoETFs with exposure to Concert Pharmaceuticals, Inc. : December 8, 2016 (NASDAQ:CNCE)
www.capitalcube.com - December 8 at 4:02 PM
bloomberg.com logoTrump Team Said to Consider Thiel Associate O’Neill for FDA (3) (NASDAQ:CNCE)
washpost.bloomberg.com - December 8 at 6:46 AM

Social

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2017?

6 analysts have issued 12 month price objectives for Concert Pharmaceuticals' shares. Their predictions range from $23.00 to $32.00. On average, they expect Concert Pharmaceuticals' stock price to reach $25.50 in the next twelve months.

When will Concert Pharmaceuticals announce their earnings?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

  • Aegis analysts commented, "Concert Pharmaceutical's drug discovery platform involves replacing the hydrogen atom of an already approved drug, or a first-in-class drug candidate, with a heavier deuterium atom. The substitution adds significant molecular weight, increasing chemical bond stability and providing the potential for improved effectiveness, safety, or tolerability. The deuterium analog are not expected to result in material changes to a compound's biochemical potency or selectivity. Thus, Concert's approach has inherent reduced R&D risk relative to a company pursuing a novel molecule discovery. Concert currently has six drug candidates in clinical development and a strong track record - The company has previously developed and sold two compounds at multiple-billion dollar valuations, i.e., Otsuka's purchase of Avanir and Teva's purchase of Auspex. With multiple shots on goal ( 5 programs at various stages of development by Concert or its partners), and better probability of clinical development success than compounds at similar development stage, we believe the company is positioned well to drive upside potential." (1/23/2017)
  • According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (1/3/2017)

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (3.08%), Numeric Investors LLC (2.06%), Renaissance Technologies LLC (1.96%), Alyeska Investment Group L.P. (1.60%), State Street Corp (1.57%) and Dimensional Fund Advisors LP (1.39%). Company insiders that own Concert Pharmaceuticals stock include Nancy Stuart, Pauline Mcgowan, Robert Silverman, Roger D Tung, Ronald W Barrett, Thomas G Auchincloss and Wilfred E Jaeger.

Who sold Concert Pharmaceuticals stock? Who is selling Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Allianz Asset Management AG, Dimensional Fund Advisors LP and Frontier Wealth Management LLC.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Turner Investments LLC, Russell Investments Group Ltd., Alyeska Investment Group L.P., Trexquant Investment LP, FMR LLC, State Street Corp and GSA Capital Partners LLP. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung and Thomas G Auchincloss.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Concert Pharmaceuticals stock cost?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $9.33.

Concert Pharmaceuticals (NASDAQ:CNCE) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Earnings History Chart

Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Dividend History Chart

Dividend Payments by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Last Updated on 2/23/2017 by MarketBeat.com Staff